Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) have been given an average recommendation of “Moderate Buy” by the five research firms that are presently covering the stock, Marketbeat.com reports. Two research analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $42.60.

A number of brokerages recently commented on COLL. Needham & Company LLC restated a “hold” rating on shares of Collegium Pharmaceutical in a research note on Friday, August 9th. Truist Financial increased their target price on Collegium Pharmaceutical from $40.00 to $42.00 and gave the stock a “buy” rating in a research report on Friday, August 9th. Piper Sandler reiterated a “neutral” rating and set a $37.00 price objective on shares of Collegium Pharmaceutical in a research note on Friday, October 11th. HC Wainwright increased their price objective on Collegium Pharmaceutical from $47.00 to $50.00 and gave the stock a “buy” rating in a report on Thursday, September 5th. Finally, StockNews.com cut Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, October 23rd.

Insider Activity at Collegium Pharmaceutical

In other Collegium Pharmaceutical news, EVP Shirley R. Kuhlmann sold 19,248 shares of the firm’s stock in a transaction dated Thursday, September 5th. The stock was sold at an average price of $38.30, for a total value of $737,198.40. Following the sale, the executive vice president now owns 120,161 shares of the company’s stock, valued at $4,602,166.30. This trade represents a 13.81 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Thomas B. Smith sold 9,593 shares of the business’s stock in a transaction dated Friday, September 13th. The stock was sold at an average price of $36.62, for a total value of $351,295.66. Following the transaction, the executive vice president now directly owns 53,816 shares of the company’s stock, valued at $1,970,741.92. The trade was a 15.13 % decrease in their position. The disclosure for this sale can be found here. 3.98% of the stock is owned by corporate insiders.

Institutional Trading of Collegium Pharmaceutical

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Pacer Advisors Inc. boosted its holdings in shares of Collegium Pharmaceutical by 31.8% in the 2nd quarter. Pacer Advisors Inc. now owns 3,408,369 shares of the specialty pharmaceutical company’s stock worth $109,749,000 after purchasing an additional 821,541 shares in the last quarter. Rubric Capital Management LP boosted its stake in Collegium Pharmaceutical by 27.2% in the second quarter. Rubric Capital Management LP now owns 2,333,500 shares of the specialty pharmaceutical company’s stock worth $75,139,000 after buying an additional 499,473 shares in the last quarter. Assenagon Asset Management S.A. grew its position in Collegium Pharmaceutical by 411.1% during the second quarter. Assenagon Asset Management S.A. now owns 362,137 shares of the specialty pharmaceutical company’s stock valued at $11,661,000 after acquiring an additional 291,286 shares during the last quarter. Victory Capital Management Inc. raised its stake in shares of Collegium Pharmaceutical by 43.6% during the third quarter. Victory Capital Management Inc. now owns 710,688 shares of the specialty pharmaceutical company’s stock worth $27,461,000 after acquiring an additional 215,874 shares in the last quarter. Finally, Emerald Advisers LLC lifted its holdings in shares of Collegium Pharmaceutical by 27.2% in the 3rd quarter. Emerald Advisers LLC now owns 827,302 shares of the specialty pharmaceutical company’s stock worth $31,967,000 after acquiring an additional 177,129 shares during the last quarter.

Collegium Pharmaceutical Price Performance

NASDAQ COLL opened at $29.96 on Friday. The company has a quick ratio of 0.88, a current ratio of 0.97 and a debt-to-equity ratio of 3.43. The company has a market cap of $966.21 million, a PE ratio of 12.91 and a beta of 0.95. Collegium Pharmaceutical has a 52 week low of $25.16 and a 52 week high of $42.29. The firm’s 50-day simple moving average is $35.69 and its two-hundred day simple moving average is $34.77.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.